금은화 추출물이 폐암치료제 gefitinib의 약물동태에 미치는 영향

The objective of this study was to estimate the potential herb drug interaction between gefitinib and Lonicerajaponica (LJ) by evaluating changes in gefitinib pharmacokinetics following single and multiple oral doses of LJ in rats. Firstly, to determine basic pharmacokinetics of gefitinib, rat pharmacokinetics after 3, 10 and 30 mg/kg single intravenousand oral administration of gefitinib was executed. Secondly, single and 7-day repeated oral dose pharmacokinetics of gefitinib(10 mg/kg) after pretreatment with saline or LJ extract (500 mg/kg) were performed. In addition, the effect of fecal and urinaryrecovery after co-treatment with LJ and the inhibition of CYP3A4 by LJ was evaluated. Gefitinib showed dose-independentpharmacokinetics at intravenous and oral doses of 3−30 mg/kg and the pharmacokinetic parameters of gefitinibfollowing single and multiple doses were not significantly affected by pretreatment with LJ extract. Fecal and urinary recoveryof gefitinib was not significantly different between groups and LJ extract did not inhibit CYP3A4, main metabolic enzymeof gefitinib, activity until the concentration reached 300 μg/mL. These indicated that pharmacokinetics of gefitinib was notsignificantly affected by co-treatment with LJ extract. KCI Citation Count: 0